Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stege

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomasR Stege, M Grande, K Carlström, et al.
The Prostate|November 14, 2000
Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cellsM Grande, K Carlström, R Stege, et al.
The Prostate|January 1, 1989
PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological gradingM Hasenson, B Lundh, R Stege, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patientsM Grande, K Carlström, B L Rozell, et al.
The Prostate|January 1, 1987
Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapyR Stege, N Fröhlander, K Carlström, et al.
The Journal of Urology|August 1, 1990
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinomaR Stege, B Lundh, B Tribukait, et al.
American Journal of Clinical Oncology|January 1, 1988
Single drug polyestradiol phosphate therapy in prostatic cancerR Stege, K Carlström, L Collste, et al.
The Journal of Urology|September 1, 1992
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinomaR Stege, B Tribukait, B Lundh, et al.
The Prostate|December 5, 2000
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinomaM Grande, K Carlström, B Lundh Rozell, et al.
Lakartidningen|October 14, 1992
[Parenteral estrogen--a safe therapeutic alternative in prostatic cancer seen from the cardiovascular point of view?]P Henriksson, R Stege, L Collste, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000
Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomasR Stege, M Grande, K Carlström, et al.
The Prostate|November 14, 2000
Estrogens increase the endothelial nitric oxide synthase (ecNOS) mRNA level in LNCaP human prostate carcinoma cellsM Grande, K Carlström, R Stege, et al.
The Prostate|January 1, 1989
PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological gradingM Hasenson, B Lundh, R Stege, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patientsM Grande, K Carlström, B L Rozell, et al.
The Prostate|January 1, 1987
Steroid-sensitive proteins, growth hormone and somatomedin C in prostatic cancer: effects of parenteral and oral estrogen therapyR Stege, N Fröhlander, K Carlström, et al.
The Journal of Urology|August 1, 1990
Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinomaR Stege, B Lundh, B Tribukait, et al.
American Journal of Clinical Oncology|January 1, 1988
Single drug polyestradiol phosphate therapy in prostatic cancerR Stege, K Carlström, L Collste, et al.
The Journal of Urology|September 1, 1992
Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinomaR Stege, B Tribukait, B Lundh, et al.
The Prostate|December 5, 2000
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinomaM Grande, K Carlström, B Lundh Rozell, et al.
Lakartidningen|October 14, 1992
[Parenteral estrogen--a safe therapeutic alternative in prostatic cancer seen from the cardiovascular point of view?]P Henriksson, R Stege, L Collste, et al.
Pageof 5